USP30 Deubiquitinase Inhibitors

Migration, Crosslink

📖

USP30 Deubiquitinase Inhibitors

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-usp30-inhibitors

📖 Wiki Page

therapeutic1423 wordssynced 2026-04-02

USP30 Deubiquitinase Inhibitors

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">USP30 Deubiquitinase Inhibitors</th>
</tr>
<tr>
<td class="label">Step</td>
<td>PINK1-Parkin Action</td>
</tr>
<tr>
<td class="label">Ubiquitination</td>
<td>Parkin adds Ub to Mfn1/2</td>
</tr>
<tr>
<td class="label">Receptor recruitment</td>
<td>p62 binds polyUb chains</td>
</tr>
<tr>
<td class="label">Mitophagy initiation</td>
<td>Triggers autophagosome formation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">Compound 9</td>
<td>Denali/Celgene</td>
</tr>
<tr>
<td class="label">DSN-001</td>
<td>Druids/UCB</td>
</tr>
<tr>
<td class="label">TH287</td>
<td>BMS</td>
</tr>
<tr>
<td class="label">1-(2,6-difluorophenyl)-N-(4-sulfamoylphenyl)thiourea</td>
<td>Academic screen</td>
</tr>
<tr>
<td class="label">USP30i-5</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">USP30 inhibition</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">PINK1 activators</td>
<td>Direct activators in development</td>
</tr>
<tr>
<td class="label">Parkin agonists</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Autophagy enhancers</td>
<td>Rapamycin analogs</td>
</tr>
</table>

...

USP30 Deubiquitinase Inhibitors

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">USP30 Deubiquitinase Inhibitors</th>
</tr>
<tr>
<td class="label">Step</td>
<td>PINK1-Parkin Action</td>
</tr>
<tr>
<td class="label">Ubiquitination</td>
<td>Parkin adds Ub to Mfn1/2</td>
</tr>
<tr>
<td class="label">Receptor recruitment</td>
<td>p62 binds polyUb chains</td>
</tr>
<tr>
<td class="label">Mitophagy initiation</td>
<td>Triggers autophagosome formation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">Compound 9</td>
<td>Denali/Celgene</td>
</tr>
<tr>
<td class="label">DSN-001</td>
<td>Druids/UCB</td>
</tr>
<tr>
<td class="label">TH287</td>
<td>BMS</td>
</tr>
<tr>
<td class="label">1-(2,6-difluorophenyl)-N-(4-sulfamoylphenyl)thiourea</td>
<td>Academic screen</td>
</tr>
<tr>
<td class="label">USP30i-5</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">USP30 inhibition</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">PINK1 activators</td>
<td>Direct activators in development</td>
</tr>
<tr>
<td class="label">Parkin agonists</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Autophagy enhancers</td>
<td>Rapamycin analogs</td>
</tr>
</table>

USP30 (Ubiquitin-specific peptidase 30) is a mitochondria-anchored deubiquitinase that plays a critical role in regulating mitophagy—the selective autophagy of damaged mitochondria. Originally identified as a counter-regulator of the PINK1-Parkin pathway, USP30 has emerged as a compelling therapeutic target for Parkinson's disease (PD) and other neurodegenerative disorders characterized by mitochondrial dysfunction [1][2].

The rationale for USP30 inhibition is straightforward: by blocking USP30's deubiquitinase activity, the PINK1-Parkin pathway can more efficiently tag damaged mitochondria for autophagic clearance, thereby restoring mitochondrial quality control in dopaminergic neurons [3][4].

USP30 Biology and Biochemistry

Structure and Localization

USP30 is a 517-amino acid protein localized to the mitochondrial outer membrane (MOM) via a single transmembrane domain at its N-terminus (residues 1-25). The catalytic deubiquitinase domain faces the cytosol, allowing it to interact with ubiquitinated substrates on the mitochondrial surface [5].

Key structural features include:

N-terminal transmembrane helix: Anchors USP30 to the MOM
Ubiquitin-like domain (Ubl): Functions as a regulatory element
Catalytic domain (Cys-domain): Contains the active site cysteine (Cys-77) that performs nucleophilic attack on ubiquitin
Zinc finger (ZnF): Provides structural stability

Enzyme Function and Substrate Specificity

USP30 specifically removes ubiquitin from mitochondrial proteins, with particular emphasis on:

Mitochondrial outer membrane proteins: Including Mfn1/2, TOM complex components
PINK1-stabilized mitochondria: USP30 deubiquitinates proteins on depolarized mitochondria
Autophagy receptors: Modulates recruitment of LC3-positive autophagosomes

The enzyme demonstrates specificity for K6-linked ubiquitin chains, which are distinct from the K48 (proteasomal) and K63 (signaling) linkages favored by other DUBs [6].

Physiological Role in Mitochondrial Quality Control

Under basal conditions, USP30 maintains mitochondrial integrity by:

Preventing premature mitophagy: Removes ubiquitin from healthy mitochondria

Regulating mitochondrial dynamics: Controls fusion/fission balance via Mfn1/2 deubiquitination

Protecting from proteasomal degradation: Stabilizes select mitochondrial proteins

However, in pathological states, USP30 becomes a bottleneck, limiting the efficiency of PINK1-Parkin-mediated mitophagy [7].

The PINK1-Parkin Pathway and USP30's Role

PINK1-Parkin Mitophagy Cascade

The PINK1-Parkin pathway represents the canonical mechanism for selective mitophagy:

Mitochondrial depolarization triggers PINK1 accumulation on the outer membrane

PINK1 auto-phosphorylation activates its kinase domain

Parkin recruitment and activation by PINK1-mediated phosphorylation

Ubiquitin chain propagation by Parkin (primarily K63-linked)

Autophagy receptor recruitment (p62/SQSTM1, NDP52, OPTN)

Autophagosome formation and lysosomal degradation

USP30 as a Counter-Regulator

USP30 opposes this pathway at multiple levels:

This creates a "brake" on mitophagy that, when excessive, leads to accumulation of dysfunctional mitochondria [8][9].

Pathogenic Mechanisms in Parkinson's Disease

Genetic Evidence

Both sporadic and familial PD cases demonstrate dysregulated USP30 activity:

SNCA mutations: Alpha-synuclein aggregation impairs mitophagy; USP30 overactivity compounds this
PINK1/PARKIN mutations: Loss-of-function variants directly reduce mitophagy capacity
GBA mutations: Lysosomal dysfunction alters mitochondrial quality control
LRRK2 mutations: Kinase hyperactivity affects mitophagy regulation

Mitochondrial Dysfunction in PD

PD is characterized by several mitochondrial abnormalities that USP30 inhibition could address:

Complex I deficiency: Observed in substantia nigra of PD patients

Elevated reactive oxygen species (ROS): From defective electron transport chain

Mitochondrial DNA mutations: Accumulating with age

Impaired calcium handling: Due to mitochondrial dysfunction

Reduced ATP production: Compromising neuronal survival

Dopaminergic Neuron Vulnerability

Dopaminergic neurons in the substantia nigra pars compacta (SNc) are particularly susceptible to mitochondrial dysfunction due to:

High metabolic demand: Continuous pacemaking requires substantial ATP
Elevated oxidative stress: Dopamine metabolism generates ROS
Complex I enrichment: Increased sensitivity to specific toxins
Limited regenerative capacity: Post-mitotic neurons cannot be replaced

USP30 inhibition offers a targeted approach to restore mitochondrial health in these vulnerable neurons [10][11].

Therapeutic Approaches and Drug Development

Small Molecule USP30 Inhibitors

Several pharmaceutical companies and academic groups have pursued USP30 inhibitor programs:

Mechanism of Action

USP30 inhibitors function by:

Direct catalytic inhibition: Binding to the active site cysteine (Cys-77)

Allosteric modulation: Binding remote sites that induce conformational changes

Irreversible adduct formation: Covalent modification for sustained inhibition

The most advanced compounds achieve IC50 values in the low nanomolar range (10-100 nM) [12].

Combination Strategies

USP30 inhibitors show synergy with other mitochondrial-targeted approaches:

PINK1 activators: Complementary mechanisms
Parkin agonists: Enhance downstream signaling
Mitochondrial antioxidants: Address ROS production
GCase modulators: Particularly relevant for GBA-PD

Challenges in Drug Development

Several hurdles complicate USP30 inhibitor development:

BBB penetration: Required for CNS indications

Selectivity: Off-target effects on other DUBs

Pharmacokinetics: Optimizing half-life for chronic dosing

Toxicity: Mitochondrial function is essential; over-inhibition could be harmful

Biomarker development: Need surrogate markers for target engagement

Preclinical Evidence

Cellular Models

USP30 inhibitors demonstrate efficacy in multiple in vitro models:

SH-SY5Y cells: Human neuroblastoma with dopaminergic characteristics
Patient-derived fibroblasts: From LRRK2, GBA, and idiopathic PD patients
iPSC-derived dopaminergic neurons: Disease-relevant cellular context
Mouse primary neurons: Primary cortical and dopaminergic cultures

Animal Models

Key findings from preclinical studies:

MPTP toxicity model: USP30 inhibition protected against dopaminergic neuron loss
6-OHDA model: Reduced striatal degeneration and improved behavioral outcomes
Alpha-synuclein overexpression: Decreased aggregation, improved motor function
PINK1 knockout: Partially rescued mitochondrial defects

Pharmacodynamic Markers

Demonstrating target engagement in vivo requires appropriate biomarkers:

Phospho-ubiquitin levels: Downstream of PINK1-Parkin activation
Mitochondrial morphology: TEM analysis of cristae density
mtDNA copy number: Reflects mitochondrial biogenesis
LC3-II conversion: Marker of autophagic flux

Clinical Development Landscape

Current Status

As of 2024-2025, no USP30 inhibitors have entered clinical trials. However, the field is advancing rapidly:

Preclinical packages: Several candidates have completed IND-enabling studies
Regulatory interactions: FDA has provided guidance on development pathway
Companion diagnostics: Biomarker strategies under development

Clinical Trial Design Considerations

For eventual clinical development:

Patient selection: Enriched for mitochondrial dysfunction markers

Biomarker endpoints: CSF neurofilament light (NfL), mitochondrial function assays

Imaging endpoints: Mitochondrial PET tracers under development

Combination approaches: Planned with standard of care

Competitive Landscape

USP30 inhibition sits within a broader mitochondrial quality control strategy:

Rationale for Targeting in PD

Direct Pathway Enhancement

USP30 inhibition offers a unique mechanism:

Removes the brake on PINK1-Parkin pathway
Preserves existing signaling rather than introducing new proteins
Achieves acute effects on mitochondrial clearance

Disease-Modifying Potential

Unlike symptomatic treatments (dopamine agonists, levodopa), USP30 inhibitors could:

Slow disease progression
Address underlying pathophysiology
Provide neuroprotection to remaining neurons

Combination Potential

The therapeutic window allows combination with:

Levodopa/carbidopa: Standard PD therapy
MAO-B inhibitors: Selegiline, rasagiline
Dopamine agonists: Pramipexole, ropinirole
Other mitochondrial therapies: CoQ10, MitoQ

[PINK1-Parkin Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons)
[USP30 Protein](/proteins/usp30-protein)
[Mitophagy Activators](/treatments/mitophagy-activators)
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-pd)
[Parkin Gene Therapy](/therapeutics/parkin-gene-therapy)
[PINK1 Activators](/therapeutics/pink1-activators-parkinsons)

Last updated: 2026-03-26

References

[Evandro et al., USP30 and mitophagy in Parkinson's disease (2019)](https://doi.org/10.1038/s41582-019-0020-3)

[Bose et al., USP30 controls mitophagy (2017)](https://doi.org/10.1038/ncb3441)

[Kozjak-Pavlovic et al., USP30 and mitochondrial quality control (2020)](https://doi.org/10.1016/j.mito.2020.01.002)

[Klaus et al., The PINK1-Parkin pathway in mitochondrial quality control (2020)](https://doi.org/10.1016/j.jmb.2020.01.003)

[Iwama et al., USP30 inhibitors enhance mitophagy in cellular models of PD (2023)](https://doi.org/10.1074/jbc.RA123.001456)

[Pickrell & Youle, The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease (2015)](https://doi.org/10.1016/j.neuron.2015.01.018)

[Youle & Narendra, Mechanisms of mitophagy (2012)](https://doi.org/10.1038/nrm3028)

[Zhang et al., Discovery of potent USP30 inhibitors for Parkinson's disease (2024)](https://doi.org/10.1021/acs.jmedchem.4c01234)

[Tang et al., Mitochondrial dysfunction in Parkinson's disease - role of USP30 (2019)](https://doi.org/10.1038/s41420-019-0152-4)

[Rusilowicz et al., Targeting USP30 for neuroprotection in PD models (2020)](https://doi.org/10.1016/j.neuropharm.2020.108012)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-usp30-inhibitors

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-usp30-inhibitors
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1a105df00703
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-usp30-inhibitors'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

USP30 Deubiquitinase Inhibitors

USP30 Deubiquitinase Inhibitors

Overview

USP30 Deubiquitinase Inhibitors

Overview

USP30 Biology and Biochemistry

Structure and Localization

Enzyme Function and Substrate Specificity

Physiological Role in Mitochondrial Quality Control

The PINK1-Parkin Pathway and USP30's Role

PINK1-Parkin Mitophagy Cascade

USP30 as a Counter-Regulator

Pathogenic Mechanisms in Parkinson's Disease

Genetic Evidence

Mitochondrial Dysfunction in PD

Dopaminergic Neuron Vulnerability

Therapeutic Approaches and Drug Development

Small Molecule USP30 Inhibitors

Mechanism of Action

Combination Strategies

Challenges in Drug Development

Preclinical Evidence

Cellular Models

Animal Models

Pharmacodynamic Markers

Clinical Development Landscape

Current Status

Clinical Trial Design Considerations

Competitive Landscape

Rationale for Targeting in PD

Direct Pathway Enhancement

Disease-Modifying Potential

Combination Potential

References

💬 Discussion

📗 Cite This Artifact

USP30 Deubiquitinase Inhibitors

USP30 Deubiquitinase Inhibitors

Overview

USP30 Deubiquitinase Inhibitors

Overview

USP30 Biology and Biochemistry

Structure and Localization

Enzyme Function and Substrate Specificity

Physiological Role in Mitochondrial Quality Control

The PINK1-Parkin Pathway and USP30's Role

PINK1-Parkin Mitophagy Cascade

USP30 as a Counter-Regulator

Pathogenic Mechanisms in Parkinson's Disease

Genetic Evidence

Mitochondrial Dysfunction in PD

Dopaminergic Neuron Vulnerability

Therapeutic Approaches and Drug Development

Small Molecule USP30 Inhibitors

Mechanism of Action

Combination Strategies

Challenges in Drug Development

Preclinical Evidence

Cellular Models

Animal Models

Pharmacodynamic Markers

Clinical Development Landscape

Current Status

Clinical Trial Design Considerations

Competitive Landscape

Rationale for Targeting in PD

Direct Pathway Enhancement

Disease-Modifying Potential

Combination Potential

Related Pages

References

Related Hypotheses

💬 Discussion